Drugs / TP-122A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06370598 | Sep 2024 → May 2025 | pneumonia caused by pseudomonas aeruginosa infection | Technophage, SA | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Technophage, SA | Regulatory Technophage Receives Regulatory Approval to Initiate Phase 1/2a TP-122 Clinical Study in Europe technophage.pt ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-06-15 | Technophage, SA | Technophage Receives Regulatory Approval to Initiate Phase 1/2a TP-122 Clinical Study in Europe technophage.pt ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP-122A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06370598 ↗ |